First-line treatment of indolent lymphoma: Axing CHOP?

The Lancet

Volumn 381, Issue 9873, 2013, Pages 1163-1165

  Jacobson, Caron A ^a   Freedman, Arnold S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; LEUKEMIA; LEUKOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 84875818645     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61965-5     Document Type: Note

References (12)

1. Jones SE, Grozea PN, Metz EN, et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group study. Cancer 1983; 51: 1083-90.
2. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1978; 1: 533-37.
3. Bart lett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ. Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol 1994; 12: 1349-57.
4. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-32.
6. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202-08.
7. Rummel MJ, Niederle N, Maschmeyer G, et al, on behalf of the Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; published online Feb 20. http://dx.doi.org/10.1016/S0140- 6736(12)61763-2.
8. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-17.
9. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-79.
10. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
11. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607-14.
12. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 29: 4480-84.